This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

E. Coli O104 Outbreak Highlights Need For Rapid, Accurate Testing Options

Stocks in this article: VIVO

The recent E. coli outbreak making headlines in Europe and the United States has been identified as a rare and unique strain, E. coli O104:H4. The outbreak strain is a Shiga toxin 2 type producing E. coli, and is of concern because initial lab findings have revealed various characteristics that make it more virulent and toxin producing.

The most recent statistics show that 1,674 people have been infected with this strain across 13 European countries. 661 cases of HUS (Hemolytic Uremic Syndrome) and more than 16 deaths have been reported. The Centers for Disease Control and Prevention is also investigating four cases of HUS in the United States in patients that recently traveled to Germany.

This outbreak highlights the need for rapid, accurate tests that detect all strains of Shiga toxin-producing E. coli, not just a test that detects E. coli O157:H7. An early, differentiated diagnosis is critical to improving patient outcomes. Antibiotics are contraindicated and should be avoided when treating a patient suffering from Shiga toxin-producing E. coli infection. Paul Granato, Ph.D., Director of Microbiology at Laboratory Alliance of Central New York, stated, "The outbreak of diarrheal disease caused by Shiga-toxin producing Escherichia coli O104:H4 that is occurring in various parts of Europe emphasizes the need for clinical microbiology laboratories to use a test method, such as commercially available enzyme immunoassay (EIA), that will detect the presence of non-O157:H7 strains of E. coli that are capable of producing Shiga-like toxins 1 and/or 2. We know that over 50% of Shiga-toxin producing E. coli diarrheal infections that occur in the United States and other parts of the world are caused by non-O157:H7 strains of E. coli. The use of traditional culture-based methods alone may have missed or significantly delayed the detection of the E. coli O104:H4 diarrheal pathogen thereby increasing its potential for causing hemolytic syndrome and other life-threatening complications. Currently, the only way clinical laboratories can reliably screen for all possible Shiga-toxin producing E. coli that are capable of causing this disease is by using an EIA method."

Richard Eberly, Chief Commercial Officer stated, “Disease caused by E. coli can be devastating. Meridian Bioscience is prepared to support the testing needs of the global lab community in diagnosing Shiga toxin-producing E. coli with our Premier EHEC and Immuno Card STAT! EHEC products. It is our goal that the recommendations of the Centers for Disease Control (CDC) for diagnosing Shiga toxin-producing E. coli will become routine practice so that these serious infections can be detected quickly and appropriate therapies instituted.”


1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs